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REGULAR ARTICLE
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Key Points
• The 3 established
HbF genetic loci can
be summarized into 1
quantitative variable,
g(HbF), in SCD and
influence markers of
SCD severity.
• g(HbF) provides a
quantitative marker for
the genetic component
of HbF% variability,
potentially useful in
genetic and clinical
studies in SCD.
Fetal hemoglobin (HbF) is a strong modiﬁer of sickle cell disease (SCD) severity and is
associated with 3 common genetic loci. Quantifying the genetic effects of the 3 loci would
speciﬁcally address the beneﬁts ofHbF increases in patients. Here,wehave applied statistical
methods using the most representative variants: rs1427407 and rs6545816 in BCL11A,
rs66650371 (3-bp deletion) and rs9376090 inHMIP-2A, rs9494142 and rs9494145 inHMIP-2B,
and rs7482144 (Xmn1-HBG2 in the b-globin locus) to create g(HbF), a genetic quantitative
variable for HbF in SCD. Only patients aged $5 years with complete genotype and HbF
data were studied. Five hundred eighty-one patients with hemoglobin SS (HbSS) or HbSb0
thalassemia formed the “discovery” cohort. Multiple linear regression modeling rational-
ized the 7 variants down to 4 markers (rs6545816, rs1427407, rs66650371, and rs7482144)
each independently contributing HbF-boosting alleles, together accounting for 21.8% of HbF
variability (r2) in the HbSS or HbSb0 patients. The model was replicated with consistent r2
in 2 different cohorts: 27.5% in HbSC patients (N 5 186) and 23% in 994 Tanzanian HbSS
patients. g(HbF), our 4-variant model, provides a robust approach to account for the genetic
component of HbF in SCD and is of potential utility in sickle genetic and clinical studies.
Introduction
High fetal hemoglobin (HbF) levels are clinically beneficial in sickle cell disease (SCD), being associated
with longer survival1 and lower pain rates.2 Patients with SCD have higher HbF levels compared with
nonaffected adults and, within SCD, HbF levels are higher in hemoglobin SS (HbSS) compared with
HbSC individuals.3 One component of HbF variability relates to the expanded erythron secondary to
chronic hemolysis, and preferential survival of HbF-containing red cell precursors (F cells).4,5 A second
component is the innate ability for HbF synthesis based on genetic variants at 3 quantitative trait loci:
BCL11A on chromosome 2p, HMIP-2 on chromosome 6q, and Xmn1-HBG2 (rs7482144) on
chromosome 11p. Dependent upon the genetic variants investigated and analysis performed, such
variants were found to account for between 8 and ;20% of the HbF variability in SCD in studies from
the United Kingdom, United States, Brazil, Tanzania, and Cameroon.6-13 This genetic component is likely
to account for much of the variability in HbF levels in SCD patients. Consequently, it may be helpful to
quantify and summarize the effects of the respective genetic loci into a single genetic variable to
capture the essence of genetic disease alleviation through the HbF mechanism. Here, we present
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such a genetic HbF summary variable, g(HbF), which will be a
useful parameter to use as a covariate in genetic, biological, and
clinical studies in diverse SCD populations.
Subjects and methods
British patients are part of the South East London sickle gene bank
(King’s College Hospital, Guys and St Thomas’ Hospitals Trust,
Lewisham Hospital, and Queen Elizabeth Hospital Woolwich).
Written informed consent was obtained through 3 approved study
protocols (LREC 01-083, 07/H0606/165, and 12/LO/1610) and
research conducted in accordance with the Helsinki Declaration
(1975, as revised 2008).
Eight hundred ninety-two patients consented to the study, of which
785 aged over 5 years had a full dataset (genotypes and
phenotype). These 785 comprised 581 with HbSS or HbSb0
(the “discovery cohort” used for the primary analysis), 186 HbSC
(the “validation” cohort), and 18 HbSb1 thalassemia (Figure 1).
Additional validation was performed in the Muhimbili HbSS cohort,
Tanzania (N 5 994).10
Genetic variants and genotyping
We assembled an initial set of 7 known (and widely replicated)
HbF modifier variants, prioritizing those where additional functional
evidence had been generated (Table 1): BCL11A-rs142740714 and
rs654581610; HMIP-2A-rs6665037115,16 and rs937609017; HMIP-
2B-rs949414517,18 and rs949414216; Xmn1-HBG2-rs7482144.6,19,20
A combination of 3 genotyping methodologies was used: (1)
“manual” genotyping in the laboratory (all variants) by the TaqMan
procedure, except rs66650371, which was assayed by capillary
electrophoresis (Applied Biosystems, Foster City, CA), as previously
described17; (2) a genome-wide chip (Illumina Infinium Multi-Ethnic
Genotyping Array); (3) imputation with public and in-house reference
haplotypes (see supplemental Methods).
Phenotypes
HbF% (measured by high-performance liquid chromatography;
BioRad Variant II), no red cell transfusion for .3 months, off
hydroxyurea for .3 months, and not pregnant, were retrospectively
collected. For the 581 HbSS/HbSb0 discovery set, median HbF
was 4.5% (interquartile range: 1.9% to 8.8%) (supplemental
Figure 1).
We estimated global disease severity using “hospitalization rate” as
a measure of pain frequency, mortality, and laboratory results. Mean
hospitalization rates were calculated for King’s College Hospital
adults over 10 years (2004-2013), dividing an individual’s number
of hematology admissions by the number of observed years. For the
302 patients with HbSS/HbSb0, median mean hospitalization rate
was 0.25 per year (interquartile range: 0-0.71) (supplemental
Figure 2). Mortality outcome was available for the 302 adults
(1 January 2004 to 31 July 2015). Steady-state laboratory values
(hemoglobin, white blood cells) over a 10-year period (2004-2013)
were averaged for 278 patients.
Building and validating the genetic model for HbF%
Genetic association between the 7 genetic variants (as normalized
genotype scores) and HbF [ln(%HbF)] was investigated by linear
regression (using STATA12) under an additive allelic model.
Manual linear regression modeling was carried out in the HbSS/
HbSb0 thalassemia “discovery group” (see supplemental Methods).
We then validated the model, g(HbF), in 2 replication groups: (1)
our own HbSC subgroup (N 5 186) and (2) a Tanzanian HbSS
cohort (N 5 994).10
Initial sample 892 [female 516, male 376]
HbS0 thal: 7
Valid HbF 809
HbSS: 574
HbSC only 186
HbSC: 186HbS+ thal: 18
Remove 83 samples
without validated HbF
Remove 17 patients aged
5 years at HbF sampling
Remove 7 samples without
full genotype data (7 variants)
HbSS and HbS0 thal 581
Primary analysis: discovery
cohort
Verification
analysis
Age at HbF 5: 792
Full genotype/
phenotype data: 785
Hospitalization
analysis
With 4 variant
data 302
Mortality
analysis
With 4 variant
data 302
Figure 1. Flow chart illustrating fate of the initial 892
samples.
236 GARDNER et al 13 FEBRUARY 2018 x VOLUME 2, NUMBER 3
Testing for association of g(HbF)with clinical severity
Tests for genetic association of individual DNA variants with
Ln(HbF%) were performed by linear regression (in STATA) with
age (at sampling) and sex as covariates in an additive allelic model.
Age was squared, as this was better correlated with outcome. See
supplemental Methods.
Results
Summary variables combining genotypes across HbF modifier
loci have been found to be associated with clinical severity in
b-thalassemia21 and have also been explored in SCD.10,22-24 To
represent the relationship between genetic factors and HbF more
accurately and to build a summary variable that is robust across
diverse SCD cohorts, we used regression modeling of the effect of
7 known modifier variants (Table 1) on HbF levels in 581 SCD
patients with HbSS and HbSb0 genotypes. We targeted genetic
variants at the 3 major HbF loci that have been widely replicated and
implicated as causative genetic variants. Preliminary analysis using
basic regression with age/sex only yielded a model with r2 5 0.11.
Adding a-thalassemia (in a subset of patients, N 5 273, with
a-globin status available) showed that a-thalassemia was not
associated with HbF levels in our cohort (r2 5 0.11 with a-globin
status, P 5 .23 for a-globin status). We therefore did not pursue
using a-globin status. Basic regression with the 7 genetic
variants only produced a model with r2 5 0.23. Putting age,
sex, and the 7 genetic variants together in the model increased
the r2 to 0.3167 (supplemental Figure 3). As age and sex are
roughly orthogonal to the variants, our subsequent analyses did
not control for age/sex.
Final regression analysis resulted in a model utilizing 4 variants:
rs1427407, rs6545816 (both BCL11A), rs66650371 (HMIP-2A),
and rs7482144 (Xmn1-HBG2) (Table 1). rs9376090, rs9494142,
or rs9494145 (all at HMIP-2) did not improve the model and
were considered redundant. Applying this model, the predicted
Ln(HbF%), g(HbF), would be calculated as g(HbF) 5 1.89 1
0.143 rs65458161 0.33 rs14274071 0.133 rs666503711
0.1 3 rs7482144 (genotype for each variant 50, 1, or 2,
according to the number of HbF-boosting alleles).
To calculate a genetically predicted HbF% (rather than Ln(HbF%)),
the reader should antilog the g(HbF) formula. Nevertheless, the
formula stated above should be used for generating the covariate
for statistical analyses.
g(HbF) underlies 22% (r25 0.2178, P , .0001) of the variability in
HbF levels in our discovery group, and confirming its robustness,
23% in the Muhimbili “replication group” (N 5 994) and 27.5% in
HbSC patients (Table 1). In HbSC disease, the comparatively large
effect of g(HbF) is likely due to the less severe pathology and thus
smaller influence of nongenetic factors.
HbF levels affect the severity of SCD; patients with higher levels of
HbF have fewer complications and live longer.1,2 We tested the
influence of g(HbF) on hospitalization rate in HbSS/HbSb0 patients
and detected tentative association (N 5 304, b 5 0.47, P5 .031),
suggesting that a 2.7-fold increase in g(HbF) would result in a 38%
decrease in hospitalization frequency. Nevertheless, the g(HbF) for
frequently admitted patients was not significantly changed. g(HbF)
was, however, associated with hemoglobin (N 5 278, b 5 17.871,
P , .001). We found no association of g(HbF) with mortality or
white blood cells.
Discussion
Our cohort has potential power to investigate the influence of g(HbF)
on global measures of disease severity. International collaboration,
larger sample sizes, adding new loci as they are discovered, and
development of the formula will be required to realize the utility of the
g(HbF) variable. We saw no significant benefit for including the
HMIP-2B locus17 in g(HbF). This will be revisited once the underlying
functional variant has been identified.
We believe that estimating g(HbF), or similar genetic summary
variables, will add significant value to genetic and clinical studies,
either to test the influence of genetic modifiers on outcomes or to
act as a covariate to adjust for such effects. The comparatively
larger value of g(HbF) for HbSC patients suggests that it is able to
isolate the genetic component of HbF% from the component
reactive to disease severity. Using a preset formula, such as the one
proposed here, will be especially useful in smaller and medium-size
cohorts or clinical trials, where de novo modeling is meaningless.
Table 1. Seven variants representing the 3 major HbF quantitative trait loci that were rationalized to a 4-variant model (g(HbF)) to represent
the genetic component of HbF in SCD
Gene Variant HbF-boosting allele
Allele frequency g(HbF) model
London, United
Kingdom
Dar es Salaam,
Tanzania
Coefficient (b)
(95% confidence interval) P
BCL11A (Chr 2) rs6545816 (A.C) C 0.34 0.36 0.14 (0.08-0.19) ,.001
rs1427407 (G.T) T 0.26 0.21 0.30 (0.26-0.35) ,.001
HMIP (HBSL1-MYB intergenic
polymorphism on Chr 6)
2A rs9376090 (T.C) C 0.01
rs66650371 (TAC.—) 3bp del 0.04 0.02 0.13 (0.08-0.17) ,.001
2B rs9494142 (T.C) C 0.05
rs9494145 (T.C) C 0.05
HBG2-Xmn1 (b-globin gene
cluster on Chr 11)
rs7482144 (G.A) A 0.07 0.01 0.10 (0.05-0.15) ,.001
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